About Nabriva
Nabriva is a company based in Vienna (Austria) founded in 2006. Nabriva has raised $193.08 million across 5 funding rounds from investors including Novartis, Hercules Capital and Orbimed. Nabriva has completed 1 acquisition, including Zavante. Nabriva offers products and services including XENLETA, CONTEPO, and SIVEXTRO. Nabriva operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Vienna, Austria
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nabriva Therapeutics Plc
-
Annual Revenue
$36.94 M (USD)27.82as on Dec 31, 2022
-
Net Profit
-$57.19 M (USD)-15.64as on Dec 31, 2022
-
EBITDA
-$55.27 M (USD)-14.74as on Dec 31, 2022
-
Total Equity Funding
$193.08 M (USD)
in 5 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Dec 21, 2018
-
Investors
Novartis
& 9 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nabriva
Nabriva is a publicly listed company on the OTC with ticker symbol NBRVF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nabriva
Nabriva offers a comprehensive portfolio of products and services, including XENLETA, CONTEPO, and SIVEXTRO.
Treats serious bacterial infections in patients.
Addresses urinary tract and other infections.
Promoted for skin and soft tissue infections.
People of Nabriva
Unlock access to complete
Funding Insights of Nabriva
Nabriva has successfully raised a total of $193.08M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nabriva
Nabriva has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Hercules Capital and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Nabriva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nabriva
Nabriva has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zavante.
Investment portfolio details for Nabriva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Nabriva
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nabriva
Detailed financials for Nabriva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nabriva Comparisons
Peer comparison for Nabriva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nabriva
Nabriva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Nabriva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nabriva
Complete news archive for Nabriva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nabriva
Nabriva was founded in 2006.
Nabriva is headquartered in Vienna, Austria.
Nabriva is a funded company, having raised a total of $193.08M across 5 funding rounds to date.
Annual revenue of Nabriva is $36.94M as on Dec 31, 2022.
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABPVABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDAMAA filing) and pediatric indications (phase I).
Nabriva's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Nabriva offers XENLETA, CONTEPO, and SIVEXTRO.
Yes, Nabriva is publicly traded on OTC under the ticker symbol NBRVF.
Nabriva has made 1 acquisition, including Zavante.
Nabriva has 10 investors. Key investors include Novartis, Hercules Capital, Orbimed, HBM Healthcare Investments, and EcoR1.
The ticker symbol of Nabriva is NBRVF on OTC.